Form 4: Protalix BioTherapeutics CEO Receives Stock Grant
Insider Transaction (Form 4)
Dror Bashan, PRESIDENT AND CEO and a Director of Protalix BioTherapeutics, Inc., reported multiple transactions in common stock on September 3, 2026.
Summary
- Grant/award: acquired 320,000 Stock Option (Right to Buy) on September 3, 2026; holds 320,000 after (Direct).
- Grant/award: acquired 160,000 Restricted Stock Units on September 3, 2026; holds 160,000 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Dror Bashan — Director, Officer (PRESIDENT AND CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-03 | Grant/award | Stock Option (Right to Buy) | 320,000 | — | — | 320,000 |
| 2026-09-03 | Grant/award | Restricted Stock Units | 160,000 | — | — | 160,000 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-03 | Grant/award (320,000 shares) |
| 2026-09-03 | Grant/award (160,000 shares) |
Keywords
insider transaction, Form 4, PLX, Protalix BioTherapeutics, Inc., neutral, Dror Bashan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.